- Home
- GIGM vs ZLAB Comparison
GIGM vs ZLAB Comparison
Compare GIGM & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | ZLAB |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Taiwan | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 2.0B |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GIGM | ZLAB |
|---|---|---|
| Price | $1.47 | $18.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $53.52 |
| AVG Volume (30 Days) | 11.3K | ★ 895.0K |
| Earning Date | 10-30-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,397,000.00 | ★ $441,629,000.00 |
| Revenue This Year | N/A | $26.16 |
| Revenue Next Year | N/A | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.11 | ★ 24.14 |
| 52 Week Low | $1.38 | $16.82 |
| 52 Week High | $1.89 | $44.34 |
Technical Indicators
Market Signals| Indicator | GIGM | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 50.82 |
| Support Level | $1.45 | $18.01 |
| Resistance Level | $1.49 | $19.83 |
| Average True Range (ATR) | 0.05 | 0.57 |
| MACD | -0.00 | 0.31 |
| Stochastic Oscillator | 11.11 | 64.91 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.